| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Abemaciclib | Abemaciclib Mesylate | VL4990001 | View CAS 1231930-82-7 |
| Abemaciclib | 2-Methanol Abemaciclib | VE0010004 | View CAS 2138499-06-4 |
Abemaciclib Related Compound
It works by preventing an aberrant protein from signalling cancer cells to proliferate. This aids in slowing or stopping the spread of cancer cells.
References
- “Abemaciclib Approved for Breast Cancer.” National Cancer Institute, Cancer.gov, 26 Oct.2017, www.cancer.gov/news-events/cancer-currents-blog/2017/fda-abemaciclib-breast cancer.
- “Abemaciclib: MedlinePlus Drug Information.” Medlineplus.gov, 2022,medlineplus.gov/druginfo/meds/a617049.html.
- PubChem. “Abemaciclib.” @Pubchem, PubChem, 2023,pubchem.ncbi.nlm.nih.gov/compound/Abemaciclib#:~:text=Abemaciclib%20specifically%20inhibits%20CDK4%20and,and%20inhibiting%20cancer%20cell%20growth..
FAQ’s
Abemaciclib is what kind of medication ?
Abemaciclib belongs to the cyclin-dependent kinase (CDK) inhibitor group of medicines. These medications inhibit the function of two proteins, CDK4 and CDK6, which regulate cell division.
How does abemaciclib work in the treatment of breast cancer?
Abemaciclib belongs to a class of drugs known as kinase inhibitors. It works by preventing an inappropriate protein from signalling cancer cells to proliferate. This aids in slowing or stopping the spread of cancer cells.
What is the mechanism of action of Abemaciclib?
Abemaciclib selectively inhibits CDK4 and 6, preventing the phosphorylation of Rb proteins in early G1. Inhibiting Rb phosphorylation limits the CDK-mediated G1-S phase transition, which stops the cell cycle in the G1 phase, suppresses DNA synthesis, and inhibits cancer cell development.
